Vanguard Group’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-623,488
Closed -$69.3K – 4613
2022
Q4
$69.3K Sell
623,488
-8,279
-1% -$5.28K ﹤0.01% 4420
2022
Q3
$669K Hold
631,767
– – ﹤0.01% 4133
2022
Q2
$1.18M Hold
631,767
– – ﹤0.01% 4027
2022
Q1
$2.26M Buy
631,767
+119,929
+23% +$589K ﹤0.01% 3907
2021
Q4
$4.41M Buy
511,838
+63,384
+14% +$403K ﹤0.01% 3683
2021
Q3
$3.41M Buy
448,454
+20,500
+5% +$173K ﹤0.01% 3863
2021
Q2
$2.84M Sell
427,954
-206,948
-33% -$1.3M ﹤0.01% 3856
2021
Q1
$7.68M Buy
+634,902
New +$12.6M ﹤0.01% 3306

Other funds holding LHDX

Vanguard Group's LHDX Position: Q1 2023 in Review

Vanguard Group sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 623,488 shares — an estimated $69.3K sold.

Vanguard Group first reported a position in LHDX in Q1 2021 and held it in 8 quarters. The position peaked at $7.68M in Q1 2021. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

  • Vanguard Group reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 623,488 Lucira Health, Inc. Common Stock shares in Q1 2023, an estimated $69.3K.
  • Vanguard Group first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Vanguard Group's Lucira Health, Inc. Common Stock position peaked at $7.68M in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.